CNG-β3 Inhibitors
CNG-β3 inhibitors belong to a distinct chemical class designed to specifically target and modulate the activity of the CNG-β3 subunit, which is a component of cyclic nucleotide-gated (CNG) ion channels. These ion channels are essential for the transduction of sensory signals in various tissues, including the retina and the olfactory epithelium. By inhibiting CNG-β3, these compounds aim to interfere with the normal functioning of the ion channels, which are responsible for opening and closing in response to cyclic nucleotide binding. The development of CNG-β3 inhibitors involves advanced research methodologies, computational techniques, and experimental screening. Scientists may use a variety of approaches, such as structure-based drug design, high-throughput screening, virtual screening, pharmacophore modeling, and natural product-based screening. These strategies help identify inhibitors that interact with specific regions of the CNG-β3 protein, disrupting its role in the modulation of ion channel activity. Once inhibitors are identified, researchers conduct further studies to optimize their chemical structure, potency, and selectivity. This includes performing Structure-Activity Relationship (SAR) studies to understand the relationship between the chemical structure of the inhibitors and their inhibitory effects on CNG-β3.
Functional assays, such as patch-clamp electrophysiology, are utilized to validate the inhibitory activity of these compounds on the ion channel function in vitro. Additionally, in vivo studies may be performed to explore the efficacy of CNG-β3 inhibitors in animal models, providing insights into their effects on sensory signal transduction processes. The study of CNG-β3 inhibitors holds promise for advancing our understanding of the molecular mechanisms underlying sensory signal transduction in the visual and olfactory systems. By exploring the interactions between these inhibitors and CNG-β3, researchers aim to contribute to the broader understanding of ion channel regulation and cellular signaling processes.
SEE ALSO...
Items 1 to 10 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This agent could hypothetically decrease methylation patterns within the CNGB3 promoter region, leading to enhanced transcriptional activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
By inhibiting histone deacetylases, this compound may result in an open chromatin conformation, which could inadvertently decrease CNGB3 transcription. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $95.00 $322.00 $663.00 $1438.00 | 6 | |
As an inhibitor of bacterial RNA polymerase, its off-target effects in eukaryotic cells could non-specifically decrease CNGB3 mRNA synthesis. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
While zaprinast is known as a phosphodiesterase (PDE) inhibitor, it has also been shown to inhibit CNG channels, including CNG-β3, thus modulating cyclic nucleotide-mediated signaling. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
This compound might bind to DNA at the transcription initiation complex and obstruct RNA elongation, resulting in reduced CNGB3 expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
By binding to GC-rich DNA sequences, Mithramycin A could specifically inhibit the initiation of CNGB3 transcription. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Known for DNA intercalation, chloroquine could disrupt the transcription machinery′s access to the CNGB3 gene, leading to decreased expression. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
By binding to acetylated lysines on histones, JQ1 could displace transcription factors from chromatin, resulting in reduced transcription of CNGB3. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
A PDE3 inhibitor that may affect the activity of CNG-β3 channels. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
This cytidine analogue may incorporate into DNA and trap DNA methyltransferases, potentially reducing the methylation of the CNGB3 gene, thereby increasing its transcription. | ||||||